Keyphrases
Multisystem Inflammatory Syndrome in children (MIS-C)
98%
Denmark
79%
Unvaccinated
60%
HIV-exposed Uninfected children
49%
Pediatric Population
49%
Continuous Registration
49%
Metabolic Outcomes
49%
Antiviral Medicines
49%
SARS-CoV-2 Delta Variant
49%
E. Coli Meningitis
49%
Pediatric Hepatitis B
49%
Omicron Wave
49%
Prospective Cohort Study
49%
Chronic Hepatitis C
49%
Direct-acting Antivirals
49%
Possible Complications
49%
Early Treatment
49%
Hospital Admission
49%
Vaccination Status
49%
National Cohort Study
49%
Liver Cirrhosis
49%
Clinical Phenotype
49%
HIV-unexposed
49%
Liver Cancer
49%
Liver Fibrosis
49%
Hepatitis C Virus Infection
49%
High Efficacy
49%
Virus
49%
Hepatitis B/C Virus
49%
Diabetic
49%
Hemoglobin A1c (HbA1c)
49%
Primary Intention
49%
Chronic Hepatitis B Virus
37%
B Hepatitis
37%
Lumbar Puncture
32%
SARS-CoV-2 Infection
30%
Non-specific Diagnoses
24%
Infectious Diseases
24%
Antibiotic Use
24%
Self-monitoring of Blood Glucose
21%
Ventriculitis
16%
Gentamicin
16%
Underlying Disease
16%
Cephalosporins
16%
Risk Factors
16%
Empyema
16%
Monotherapy
16%
Escherichia Coli
16%
Invasive Procedures
16%
Intravenous Antibiotics
16%
Medicine and Dentistry
Infection
100%
Serositis
98%
Cohort Analysis
76%
Severe Acute Respiratory Syndrome Coronavirus 2
74%
Pediatrics
52%
Hepatitis B
49%
Liver Fibrosis
49%
Hepatitis C
49%
Liver Cancer
49%
Hepatitis B Virus
49%
Observational Study
49%
Side Effect
49%
Medicine
49%
Human Immunodeficiency Virus
49%
Chronic Hepatitis C
49%
Liver Cirrhosis
49%
Omicron Coronavirus Variant
49%
Antivirus Agent
49%
Prospective Cohort Study
49%
Escherichia coli
49%
Meningitis
49%
Bacterial Meningitis
49%
Disease
38%
Chronic Hepatitis B
37%
Lumbar Puncture
32%
Antibiotics
29%
Brain Ventriculitis
16%
Pediatric Infection
16%
Empyema
16%
Invasive Procedure
16%
Gentamicin
16%
Cephalosporin
16%
Monotherapy
16%
Adolescent
15%
Elastography
12%
Liver Disease
12%
Liver Biopsy
12%
Liver Function
12%
Fibrosis
12%
End Stage Liver Disease
12%
Hepatitis C Virus
12%
Delta Wave
5%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
78%
Hepatitis B
49%
SARS Coronavirus
49%
Side Effect
49%
Hepatitis B Virus
49%
Vaccination Policy
49%
Liver Fibrosis
49%
Liver Cancer
49%
Inflammation
49%
Delta Variant
49%
Antivirus Agent
49%
Observational Study
49%
Liver Cirrhosis
49%
Hepatitis C
49%
Prospective Cohort Study
49%
Chronic Hepatitis C
49%
Escherichia coli
49%
Bacterial Meningitis
49%
Meningitis
49%
Chronic Hepatitis B
37%
Disease
34%
Brain Ventriculitis
16%
Antibiotic Agent
16%
Monotherapy
16%
Empyema
16%
Gentamicin
16%
Cephalosporin
16%
Fibrosis
12%
End Stage Liver Disease
12%
Liver Disease
12%
Hepatitis C Virus
12%